Modern Research Associates PLLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$416,007	52
2024	Research	$412,784	51
2023	Research	$130,143	25
2022	Research	$129,242	27
2021	Research	$197,555	28
2020	Research	$34,054	11
2019	Research	$2,123	1

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $442,642 22 payments
AbbVie, Inc. $420,282 113 payments
Takeda Pharmaceuticals U.S.A., Inc. $350,898 25 payments
Pfizer Inc. $83,167 24 payments
Incyte Corporation $20,644 7 payments
LEO Pharma AS $3,630 2 payments
Galderma Laboratories, L.P. $645 2 payments

Studies the money was for Research payments · program years 2019–2025

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period $265,484 16 payments
A Phase 2B, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa $128,508 2 payments
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $111,586 14 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata $82,004 6 payments
Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $78,268 1 payment
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $66,378 7 payments
A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $49,667 2 payments
A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult and Adolescent Participants With Non Segmental Vitiligo $44,705 13 payments
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) $41,780 16 payments
A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $32,351 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.